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Abstract
Purpose: To report the initial institute experience in terms of dosimetric and technical aspects in stereotactic body
radiation therapy (SBRT) delivered using flattening filter free (FFF) beam in patients with liver lesions.
Methods and Materials: From October 2010 to September 2011, 55 consecutive patients with 73 primary or
metastatic hepatic lesions were treated with SBRT on TrueBeam using FFF beam and RapidArc technique. Clinical
target volume (CTV) was defined on multi-phase CT scans, PET/CT, MRI, and 4D-CT. Dose prescription was 75 Gy in
3 fractions to planning target volume (PTV). Constraints for organs at risk were: 700 cc of liver free from the 15 Gy
isodose, Dmax < 21 Gy for stomach and duodenum, Dmax < 30 Gy for heart, D0.1 cc < 18 Gy for spinal cord, V15 Gy <
35% for kidneys. The dose was downscaled in cases of not full achievement of dose constraints. Daily cone beam
CT (CBCT) was performed.
Results: Forty-three patients with a single lesion, nine with two lesions and three with three lesions were treated
with this protocol. Target and organs at risk objectives were met for all patients. Mean delivery time was 2.8 ± 1.0
min. Pre-treatment plan verification resulted in a Gamma Agreement Index of 98.6 ± 0.8%. Mean on-line co-
registration shift of the daily CBCT to the simulation CT were: -0.08, 0.05 and -0.02 cm with standard deviations of
0.33, 0.39 and 0.55 cm in, vertical, longitudinal and lateral directions respectively.
Conclusions: SBRT for liver targets delivered by means of FFF resulted to be feasible with short beam on time.
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Introduction
Stereotactic body radiation therapy (SBRT) has proved
its efficacy in several patient populations with primary
and metastatic limited tumours [1]. In particular, SBRT
may be appropriate for selected patients with oligo-
metastatic disease, defined as less than five lesions [2] or
with organ-confined limited volume primary tumours.
Abdominal SBRT has been reported with reference
mainly to primary and secondary liver tumours [1,3,4].
It is known that in the setting of limited tumour burden,
SBRT leads to local control rates higher than 70%-80%
[1], which may improve survival and quality of life.
RapidArc (RA) is a relative new VMAT technique
based on simultaneous optimisation of multi leaf colli-
mator (MLC) shapes, dose rate and gantry rotation
speed [5]. The technology was investigated in several
studies, showing comparable target coverage and a gen-
eral improvement in organs at risk (OAR) and healthy
tissue sparing, a reduced beam-on time and lower num-
ber of monitor units (MU) compared to other IMRT
approaches [6-13]. In a previous work we demonstrated
the feasibility and dosimetric advantage to use Volu-
metric Modulated Arc Therapy (VMAT) using RapidArc
(RA) (Varian Medical Systems, Palo Alto, CA) in SBRT
treatments of abdominal region to reduce treatment
time, compared to 3D conformal radiotherapy (3D-
CRT) and intensity modulated radiotherapy (IMRT)
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abdominal targets has been delivered by means of RA.
More recently, we reported our early experience in
terms of technical feasibility, local control rate and
acute toxicity profile of SBRT with RA for patients with
primary or secondary abdominal tumours, showing the
good toxicity profile and clinical results [15,16].
TrueBeam (Varian Medical System, Palo Alto, USA) is
a new accelerator designed for delivering both in flat-
tened filter (FF) and flattering filter free (FFF) modality
[17]. In particular, the removal of flattening filter was
shown to reduce of out-of-field dose due to the reduc-
tion of head scatter and residual electron contamination,
consequence of the exclusion of beam attenuation due
to flattened filter. Furthermore, with FFF beams the
dose rate is increased up to a factor 4 for the 10 MV
beam [18-23]. This leads to a possible reduction in
delivery time with benefit in patient discomfort and
with potential limitation of intra-fraction motion.
Some feasibility studies for SBRT using FFF beams are
present in literature [23,24] and in a recent study per-
formed in our institute we showed our early experience
in the use of FFF beams for SBRT treatments including
liver metastases, lung primitive and metastases, isolated
abdominal lymph nodes, adrenal glands, and pancreas
[25]. In the present study our attention was focused on
the sub-group of patients that underwent a strongly
hypo-fractionated treatment for which the time advan-
tage is maximum. In particular our aim was to show a
complete overview of SBRT liver protocol focusing on
technical aspects: the deliverability is evaluated by
gamma agreement index using two different devices
(MatriXX and GafChromic), the analysis of the inter-
fraction displacements by means of CBCT, and dosi-
metric objectives according to the number of lesions
treated. The evaluation of radiation-induced liver disease
(RILD), the radiobiological consequence due to the
higher dose rate, and the clinical evaluation are not aim
of this paper and these aspects will be evaluated in a
specific study.
Methods and materials
Patients selection and treatment planning
Between November 2010 and September 2011 at Istituto
Clinico Humanitas (ICH) 55 patients with 73 primary or
metastatic liver tumours were treated by TrueBeam in
an on-going phase II prospective protocol approved by
the internal ethical committee. Aim of the protocol,
approved in late 2009, was the evaluation of local con-
trol in patients with liver malignancies; secondary end-
points were the acute and late toxicities, and evaluation
of overall survival. According with Fleming approach, to
demonstrate local control of at least 80% with a power
of 90%, at least forty-four patients in three years were
necessary to complete the study. At present, all the
patients are recruited and the follow-up are ongoing
therefore no analysis regarding local control or toxicities
will be reported in the present study.
Of the patients evaluated, 11 had primary liver
tumours, and 44 had hepatic metastases from colon
(23), biliar duct-pancreas (6), breast (5), and other sites
(10). All the patients had been considered unfit for sur-
gery or other non-surgical treatments at the time of
radiation. Chemotherapy was stopped at least 3 weeks
before SBRT and withheld until disease progression.
Median patient age was 63 years (range: 43-83). Only
patients with at least 1000 cm
3 of liver free from the
disease and with ≤ than 3 lesions were considered eligi-
ble to the protocol.
Disease extension was evaluated in all cases by Com-
puted Tomography (CT) with contrast. Although they
were not inclusion criteria of the study, magnetic reso-
nance imaging (MRI) and positron emission tomogra-
phy/CT using FDG tracer (PET/CT) were acquired in
respectively 2 and 14 patients. Both MRI and PET/CT
were acquired for those patients whose treatment indi-
cation for radiotherapy was justified by these diagnostic
exams; thus PET and MRI were only an integration in
the target definition since the use of PET and MRI in
defining the tumour is under evaluation and will be
topic of future work. Computed tomography scans for
planning were acquired for all patients positioned supine
with their arms above the head; patients were immobi-
lized by means of a thermoplastic body mask including
a Styrofoam block for abdominal compression to mini-
mize internal organ motion. Contrast free and 3 phases
contrast-enhanced planning CT scans were acquired in
free quiet breathing mode at 3 mm slice thickness with
a stereotactic body frame to localise the isocentre.
Breath hold in simulation CT was not mandatory in the
study as many patients were unfit to maintain breath
hold for many seconds with the compressor. In case of
collaborative patients the simulations CT were per-
formed in voluntary exhale breath hold.
Furthermore in case of lesions located in the VII or
VIII hepatic segment or in case of liver cupola shift
greater than 5 mm on the four simulation CTs, a four
dimensional CT (4D-CT) was performed to best define
the target margin. In addition, in two cases presenting
internal clips due to previous surgery, the 4D-CT scan
was acquired and the SBRT was performed in gated
modality with internal marker tracking by 2D imaging.
This option was released in July 2011 with TrueBeam
version 1.5, and thus the first patients were not treated
with internal marker tracking. This topic will be dee-
pened in a specific paper.
The gross tumor volume (GTV) included macroscopic
disease defined on CT as well as on PET if available.
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the GTV. The planning target volume (PTV) was gener-
ated by taking into account both the internal margin
(IM) and the set-up margin (SM). Since SM was main-
tained at a minimum by the cone-beam CT (CBCT)
daily verification of set up variations, the overall CTV-
PTV margin was prescribed as 8-12 mm in the cranial-
caudal axis and 4-6 mm in the anterior-posterior and
lateral axes, allowing mainly for residual intra-fraction
target motion as well as for inaccuracies in CBCT image
interpretation [26,27]. The organs at risks (OAR) con-
sidered were: healthy liver, spinal cord, kidneys, sto-
mach, duodenum, heart, small bowel, oesophagus and
ribs, in relation with the lesion location.
The isodose distribution applied during SBRT typically
includes planned heterogeneity within the tumor
intended to intensify the dose within the tumor. In this
protocol, the isodose line prescribed to cover the PTV
was at least 67% of the prescribed dose (range 67-95%),
trying to maximizing it up to 95% [28]. Dose prescrip-
tion was set to 75 Gy in 3 consecutive daily fractions.
For OARs, plans were required to meet the following
objectives: V15 Gy (volume receiving 15 Gy) < (total liver
volume - 700 cm
3) for healthy liver, D0.1 cm3 for spinal
c o r d<1 8G y( d o s ea tav o l u m eo f0 . 1c m
3 should be
lower than 18 Gy), V15 Gy < 35% for both kidneys, V21
Gy < 1% for duodenum, small bowel, oesophagus, and
stomach, V30 Gy < 1% for heart; D30 cm
3 < 30 Gy for ribs
were considered as a secondary objective [3,29]. In case
of overlap between PTV and duodenum or stomach, the
priority was given to the OAR cropping the PTV to
comply with the OAR limits.
Treatment delivery
All plans were designed and optimised with RA techni-
que using the optimizer PROIII for a Varian TrueBeam
equipped with a Millennium multi-leaf collimator
(MLC) with a leaf width of 5 mm at the isocentre. RA
plans were designed using full (i.e. 360°) or partial (i.e.
around 200°) multiple arcs according in order to achieve
the best dose distributions. Specifically, partial arcs were
used in cases of (1) lesion located far from the median
axis (i.e. more than 10 cm) to do not collide the gantry
with the couch induced by laterality of the couch, and
(2) lesion very close to serial OARs (i.e. heart, gastro-
intestinal organs) to best protect them. Where possible,
coplanar arcs were employed to fasten the delivery time,
otherwise, non coplanar arcs arrangements were used
with two perpendicular couch positions. In particular,
the non-coplanar approach was adopted in multi-lesions
cases only. All dose distributions were computed with
the Analytical Anisotropic Algorithm (AAA) (version
10.0.28) implemented in the Eclipse planning system
with a calculation grid resolution of at maximum 2.0
mm.
Treatment was delivered in 3 consecutive working
days, with the patient keeping a 3-hour fast to avoid
gross displacement of stomach. Treatment delivery
included stereotactic frame localization in the first ses-
sion aiming to a preliminary isocentre positioning fol-
lowed by image guidance with on-line couch adjustment
at each fraction by means of cone beam CT (CBCT).
Couch repositioning was operated after automatic
matching of CBCT images to reference planning CT,
followed by manual refining. The shift values were ana-
lyzed for all patients and random (s) and systematic (Σ)
population errors were calculated according to Van
Herk approach [30]. In two cases the delivery was per-
formed in respiratory gated modality. This approach
allows the radiation beam to be turned off when respira-
tory movements place the target outside of the predeter-
mined positioning parameters, and to resume the
radiation when the target falls back within the accepted
alignment. In particular, the respiration path was
revealed with RPM system (Varian) and internal mar-
kers, previously detected on the simulation CT. The
markers were detected by instantaneous kV-portal
images acquired before each beam-on phase. On each of
these kV-portal images, a circular region of interest
(ROI) of 5 mm radius defined the theoretical marker’s
position for each projection; the radiation oncologist
could then verify the instantaneous marker’sp o s i t i o n s
to be inside the ROI, highlighting possible internal
organ motions.
Before treatment, each plan was verified to assess
dosimetric agreement between computed and delivered
dose distributions. This quality assurance process was
performed with two independent quality assurance sys-
tems (MatriXX and Gafchromic). The results of these
measurements were scored in terms of the Gamma
Agreement Index (GAI) based on the g of Low analysis
[31] with thresholds: Distance to Agreement = 3 mm,
ΔDose = 3%.
Data analysis and statistics
Technical parameters of delivery were scored in terms
of number of arcs, total number of monitor units (MU),
monitor units per Gy (MU/Gy), total beam on time,
total treatment time (the time in which the patient is in
the bunker), and isocenter shift. Dosimetric quality of
treatments was measured on the basis of dose volume
histogram (DVH) analysis. For CTV and PTV the fol-
lowing data were reported: target coverage (mean, D1%,
D95%,V 95%,V 107%) and conformity for PTV. Conformity
index (CI95%) was defined as the ratio between the
volume of patient irradiated at 95% of the prescribed
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the maximum dose (Dxcm3) and appropriate values of
VxGy (volume receiving at least x Gy) were scored. The
data were reported separately for patients with 1 lesion
and with 2-3 lesions. The Kolmogorov-Smirnoff test was
applied to the data to evaluate if the data were normally
distributed.
Results
Forty-three patients with a single lesion, nine with two
lesions and three with three lesions were treated in this
protocol, for a total of 73 isocenters. Figure 1 shows
examples of dose distributions for three representative
patients. Similar results were obtained in all patients.
PTV and organs at risk are outlined as solid lines in the
images. Table 1 reports the summary of dosimetric
results.
The Kolmogorov-Smirnoff test revealed the data were
normal distributed, thus the mean and standard devia-
tion were used to present the results. In seven patients
(i.e. 12% of cases) a 20% dose downscaling was neces-
sary to comply with the liver constraint (V15 Gy free >
700 cm
3). In all cases the maximum dose resulted
satisfactory with negligible PTV volumes exceeding
107%. Planning objectives for organs at risk were largely
met in most of the cases for both groups of patients.
The always resulted > 700 cc as requested by the con-
straints, with mean and SD values of 965 ± 141 cc and
1283 ± 706 cc for single and multi lesion patients
respectively. The higher V15 Gy free liver value for multi
lesion patients was due to the larger liver volumes of
this cohort of patients; the high mean and SD values are
a s c r i b a b l et oas i n g l ec a s ei nw h i c ht h et o t a ll i v e r
volume was 3320 cc (excluding the case, the mean value
decreases to 1039 ± 157 cc).
Pre-treatment quality assurance measurements
resulted satisfactory with a minimum deviation between
groups of less than 3% and no statistically significant
differences (98.7 ± 1.1% and 97.9 ± 1.1% for single and
multi lesion patients respectively). In all cases GAI
exceeded the acceptance threshold of 95%. Figure 2
shows an example of GAI analysis for a 2 lesions case
using both Gafchromic and MatriXX.
Patients with 1 lesion were all treated with 2 full or
partial arcs while patients with 2-3 lesions were treated
with 2 to 6 arcs (2.7 ± 1.5). The total MUs employed
Figure 1 Examples of dose distributions. Colourwash scale is reported on the figure. Solid lines represent target volumes and organs at risk.
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3594 for the others, resulting in beam on time respec-
tively of 2.3 ± 0.5 min and 3.2 ± 1.5 min, with global
range of 1.9-6.2 min (this last case was a three lesion
with six arcs plan). The overall treatment time, includ-
ing positioning, imaging, repositioning, and delivery
time, was 16.2 ± 1.7 min for the first fraction, lowering
to 12.4 ± 1.5 min for the subsequent ones. Average
MU/Gy resulted in the order of 200-250, slightly
increasing for multi-lesion patients (≈300), confirming
Table 1 summary of dosimetric results for CTV, PTV and organs at risk
CTV PTV HT Spine Ipsilateral Kidney Liver
1 les 2-3 les 1 les 2-3 les 1 les 2-3 les 1 les 2-3 les 1 les 2-3 les 1 les 2-3 les
Vol (cm
3) 22.3 ±
14.3
18.6 ±
15.4
71.2 ±
33.6
72.2 ±
45.8
- - 43.7 ±
26.7
46.0 ±
19.0
156.1 ±
40.6
154.0 ±
53.4
1349.1 ±
238.4
1708.0 ±
940.7
Mean
(Gy)
75.9 ±
1.1
75.8 ±
0.6
72.9 ±
4.1
71.5 ±
4.4
30.0 ±
5.7
30.4 ±
2.6
3.4 ± 4.2 4.1 ± 3.8 15.1 ± 4.4 16.0 ± 6.9
D0.1 cc
(Gy)
- - - - - - 9.8 ± 4.6 12.3 ±
4.2
-- - -
D1% (Gy) 77.8 ±
1.3
77.9 ±
1.0
77.4 ±
1.6
77.4 ±
1.1
---- - - - -
D95% (Gy) 73.7 ±
1.4
74.0 ±
0.8
66.7 ±
9.6
64.7 ±
9.8
---- - - - -
V10 Gy (%) - - - - 87.2 ±
17.1
85.3 ±
3.6
--- - - -
V15 Gy
(cm
3)
- - - - - - - - 10.0 ±
15.7
7.2 ± 8.9 384.2 ±
194.2
425.3 ±
234.2
V67% (%) - - 99.3 ±
2.3
99.8 ±
0.3
---- - - - -
V80% (%) - - 92.8 ±
11.9
89.0 ±
14.2
---- - - - -
V95% (%) 99.4 ±
1.56
99.5 ±
0.45
81.6 ±
26.9
73.0 ±
32.4
---- - - - -
V107% (%) 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.2 0.0 ± 0.0 - - - - - - - -
CI95% - - 1.1 ± 0.2 1.3 ± 0.5 - - - - - - - -
Figure 2 GAI evaluation for a 2 lesion case using (a)
Gafchromic and (b) MatriXX approaches.
Figure 3 Daily CBCT matching with the simulation CT for the
repositioning.
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machine output factor.
Figure 3 shows a CBCT matching with the simulation
CT for a patient with a single liver lesion. An analysis of
the corrections applied by means of a daily CBCT was
performed including all the 219 CBCT acquired for
these patients, in order to assess any systematic error
due to an inaccurate patient positioning. The mean dis-
placements found were -0.08, 0.05 and -0.02 cm with
standard deviations (SD) of 0.33, 0.39 and 0.55 cm in
vertical, longitudinal and lateral directions respectively.
The random (s) and systematic (Σ) population errors, as
defined in [30] were calculated with the following
results: s = 0.25-0.26-0.34 cm, Σ = 0.20-0.25-0.46 cm.
Discussion and Conclusions
The use of SBRT for the irradiation of primary and
metastatic tumours in several anatomical sites is becom-
ing a standard of treatment. SBRT has emerged as a
possible non invasive approach for local ablation in
some series of selected cancer patients. In particular, in
abdominal sites SBRT for patients with either organ-
confined primary tumours or oligo-metastatic disease
m a yp l a yam a j o rr o l ef o ri m p r o v i n gs u r v i v a li nac l i n i -
cally significant subset of cancer patients. Although in
most cases the radiation sterilization of a metastatic
lesion is not expected to lead to definitive cure, it could
be effective in delaying further chemotherapy or at least
this may contribute to better quality of life and local
control.
T h eh i g hd o s ep e rf r a c t i o no fS B R Ti n d u c e sah u g e
amount of MU is required to cover the target and spar-
ing the neighbour organs at risk, with a consequent
increase of the beam on time with respect to the stan-
dard RT of 2 Gy/day. In this context, the recent intro-
duction of volumetric modulated arc therapy, e.g.
RapidArc, has shown to reduce the total monitor units
and thus the treatment time in comparison with inten-
sity modulated RT (IMRT) without compromising the
target coverage as shown in many anatomical regions.
In this paper we considered the first 55 consecutive
patients that underwent SBRT on both primary and
metastatic hepatic targets, using FFF beams. In particu-
lar 43 patients presented a single lesion, 9 two lesions
and 3 presented three lesions. Removal of the flatten-
ing filter gives the possibility to deliver treatments with
higher dose rates, up to a factor 4 at 10 MV, and with
a much higher dose per pulse. The different physical
characteristics of the FFF beams (e.g. the different
beam profile) are under investigation by the scientific
community [18-23] and first preliminary clinical data
are in progress [25].
In a previous report we analyzed a cohort of patients
treated with RapidArc technique for abdominal lesions,
including abdominal lymph-nodes, pancreas, and liver
metastases [16]. All plans were optimized using flattened
beams. In particular, comparing the results obtained for
the liver metastases cohort in [16] and the data reported
in this study it appears that, though for all patients 95%
of the PTV volume received at least 67% of the prescrip-
tion dose, more patients could receive higher mean
doses to the PTV with FFF beams: mean dose to PTV
w a s6 7G yi n[ 1 6 ]a n da r o u n d7 3G yi nt h ep r e s e n t
study, PTV V95% passed from 40% to 81%, of course
the higher doses to the target implies higher doses to
OARs (e.g. liver V15Gy passed from 257 to 384 cc) but
the constraints were always respected, the mean GAI
value improved passing from 97.8% to 98.7%. On this
topic, in a recent paper, we specifically compared FFF
and FF beams from a dosimetric prospective, demon-
strating by a theorical point of view FFF beam to be
adequate in abdominal SBRT for lesions from small to
medium sizes (i.e. up to 200-300 cc), with adeguate
healthy tissue sparing and PTV coverage with respect to
flattened beams [32]. The only significant variation
between the two cohorts was the beam on time. In the
previous study, where only single hepatic metastases
were considered, around 9 minutes were necessary to
deliver the treatment while in the present group of
patients the beam on time was reduced to around 2.3
minutes (considering only the single-lesion patients),
with a cut of time of more than 350%, decreasing
patient’s discomfort and reducing intra-fraction uncer-
tainties. In both series the instantaneous delivery dose
rate was almost always at the maximum value, 600 MU/
min for FF beams and 2400 MU/min for FFF, hence the
beam on time reduction. Furthermore the data reported
in the present study showed that plans for with multi-
lesion patients are dosimetrically comparable with the
single lesion ones.
In our Institution, image-guidance by means of CBCT,
implemented in the therapeutic radiation device, is daily
used to better define and correct setup of each patient
before each fraction of the treatment. The analysis of
the daily displacements, in particular the mean values
very close to 0, show the efficiency of our set-up
method; however, the calculation of Σ and s and of the
relative margins, shows the absolute necessity of daily
repositioning by means of CBCT; the efficiency of the
set-up alone with abdominal compression and stereotac-
tic body frame is not sufficient to apply margins of 5-8
mm in the anterior-posterior and lateral axes. Daily
Image guidance has therefore allowed the minimizing of
the set-up margins from CTV to PTV, reducing the nor-
mal tissue surrounding the target close to healthy
organs in critical sites, such as in abdomen. At this pur-
pose, Eccles et al. from Princess Margaret Hospital
showed, in case of daily CBCT linked with abdominal
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mass to be lower than 5 mm in 94% patients, with mean
displacement of 1.4 mm, 2.1, and 1.0 mm in, respec-
tively, LR, AP, CC directions [25].
In conclusion, we reported our practice in the treat-
ment of liver metastases on the first 55 patients using
FFF beams, prescribing 75 Gy in 3 fractions at PTV. In
the majority of cases the beam on time was lower than
3 minutes, strongly reducing the treatment time in com-
parison with flattened filter beams, without compromis-
ing the target coverage and organs at risk sparing.
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